Biochemical composition of urine in rats with developed Guerin’s carcinoma and administration of cisplatin

A. N. Naumenko; M. V. Gorelaya; S. O. Babiy

doi:10.15421/021702

A. N. Naumenko Oles Honchar Dnipropetrovsk National University
M. V. Gorelaya Oles Honchar Dnipropetrovsk National University
S. O. Babiy Oles Honchar Dnipropetrovsk National University

Keywords: Guerin’s carcinoma, electrolytes, biochemical markers, acute renal failure

Abstract

The kidneys are very sensitive to the action not only of exogenous chemicals but also the action of compounds of endogenous origin, produced by changes in the normal metabolic processes and the development of various pathologies. Thus, tumour development has a significant impact on overall homeostasis of the body. Research into the condition of the kidneys subject to growth of tumours when cisplatin is administered is a major issue in both medical and biochemical aspects. We investigated the renal function, electrolyte composition of the blood and urinary excretion of electrolytes and individual plasma osmolarity in models of tumour growth in rats subject to introduction of cisplatin. We found that development of Guerin’s carcinoma T8 and the administration of cisplatin causes kidney damage in rats. This leads to an increase in the relative weight of the kidneys, proteinuria, and changes in activity of γ-glutamyl-transferase and lactate dehydrogenase in the kidney homogenate and urine, lower relative reabsorption and glomerular filtration. The development of Guerin’s carcinoma and administration of cisplatin in the blood and urine of rats led to a decrease in diuresis per minute by 20–60%, creatinine clearance by 50–70% and reduction in the relative water reabsorption in the renal tubules to 26% compared with the control. The administration of cisplatin led to a threefold increase in the concentration of protein, twofold increase in the concentration of albumin and sevenfold increase in the concentration of glucose in the rats’urine. In the case of rats with lesions and renal diseases (including different types of tumours) a reduction in the output of urine per minute, creatinine clearance and water reabsorption in the renal tubules was observed, indicating significant damage to the concentration and filtration functions of the kidneys. Tumour growth led to the development of hypokalemia, hyponatremia and hypochloridemia, which are major and early signs of acute renal failure. The introduction of cisplatin led to damage to the kidneys and partly normalized these indicators, as evidenced by biochemical and morphological studies. Our study shows that there is a pressing need for use of drugs which protect the kidneys when cisplatin is administered.

References

Bazaev, V. V., & Dutov, V. V. (2013). Intsidental renal cell carcinoma: Clinical and morphological features. Urology, 2, 66–68.

Benoit, D. D., Depuydt, P. O., Vandewoude, K. H., Offner, F. C., Boterberg, T., De Cock, C. A., Noens, L. A., Janssens, A. M., & Decruyenaere, J. M. (2005). Outcome in critically ill medical patients treated with renal replace¬ment therapy for acute renal failure: Comparison between patients with and those without haematological malignancies. Nephrology Dialysis Transplan¬tation, 20, 552–558. >> doi.org/10.1093/ndt/gfh637

Berkhin, E. B. (1972). Methods of experimental study of the kidneys and water-salt metabolism. Prince Publishing House, Ivanovo (in Russian).

Darmon, M., Ciroldi, M., Thiery, G., Schlemmer, B., & Azoulay, E. (2006). Clinical review: Specific aspects of acute renal failure in cancer patients. Critical Care, 10, 211–218. >> doi.org/10.1186/cc4907

Darmon, M., Thiery, G., Ciroldi, M., de Miranda, S., Galicier, L., Raffoux, E., Le Gall, J. R., Schlemmer, B., & Azoulay, E. (2005). Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Critical Care Medicine, 33, 2488–2493. >> doi.org/10.1097/01.ccm.0000181728.13354.0a

Davidson, M. B., Thakkar, S., Hix, J. K., Bhandarkar, N. D., Wong, A., & Schrei¬ber, M. J. (2004). Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. American Journal of Medicine, 116, 546–554. >> doi.org/10.1016/j.amjmed.2003.09.045

Dougan, S. J., Habtemariam, A., McHale, S. E., Parsons, S., & Sadler, P. J. (2008). Catalytic organometallic anticancer complexes. Proceding of National Academy of Sciences, 105, 28–33. >> doi.org/10.1073/pnas.0800076105

Fink, D., & Howell, S. B. (2000). How does cis-platin kill cells? In: Platinum-based drugs in cancer therapy. Humana Press., Totowa, New Jersey, 149–167. >> doi.org/10.1385/1-59259-012-8:149

Han, W. K. (2008). Biomarkers for early detection of acute kidney injury. Nephrology Rounds, 4, 304–309. >> doi.org/10.1385/1-59259-012-8:149

Hartinger, C. G., & Dyson, P. J. (2009). Bioorganometallic chemistry from teaching paradigms to medicinal applications. Chemical Society Reviews, 38, 391–401. >> doi.org/10.1039/B707077M

Heffeter, P. (2011). Anticancer activity of metal complexes: Involvement of redox processes. Antioxidants and Redox Signaling, 15(4), 85–127. >>

Huphreys, B. D., Soiffer, R. J., & Magee, C. C. (2005). Renal failure associated with cancer and its treatment: And update. Journal of the American Society of Nephrology, 4, 151–161. >> doi.org/10.1681/asn.2004100843

Johnson, R. J., Kivlighn, S. D., Kim, Y. G., Suga, S., & Fogo, A. B. (1999). Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. American Journal of Kidney Diseases, 33, 225–234. >> doi.org/10.1016/s0272-6386(99)70295-7

Kapoor, M., & Chan, G. Z. (2001). Malignancy and renal disease. Critical Care Clinics, 17, 571–598. >> doi.org/10.1016/s0749-0704(05)70199-8

Kelland, L. (2007). The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer, 11, 573–584. >> doi.org/10.1038/nrc2167

Lee, M. S. (2012). Systematic prioritization of cancer combination therapies: Are we really on target. Future Medicinal Chemistry, 2, 387–389. >> doi.org/10.4155/fmc.12.9

Loh, A. H. L., & Cohen, A. H. (2009). Drug-induced kidney disease – pathology and current concepts. Annals. Academy of Medicine, Singapore, 38(3), 240–250. >> doi.org/10.1007/978-1-4939-6436-9_12

Mandic, A., Hansson, J., Linder, S., & Shoshan, M. C. (2003). Cis-platin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. The Journal of Biological Chemistry, 9, 100–106. >> doi.org/10.1074/jbc.m210284200

Martins, N. M., Santos, N. A., Curti, C., Bianchi, M. L., & Santos, A. C. (2008). Cis-platin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. Journal of Applied Toxicology, 7, 337–344. >> doi.org/10.1002/jat.1284

Moreli, J. E., Thomas, D. R., & Wilson, M. (2006). Cachexia: Pathophysiology and clinical relevance. American Journal of Clinical Nutrition, 83, 735–743. >> doi.org/10.1177/0115426502017004203

Moskvina, L. V., Andreeva, Y. Y., & Malkov, P. G. (2013). Clinically signifi¬cant morphological parameters of renal cell carcinoma. Oncology, 4, 34–39.

Nosov, D. A. (2012). Disseminated renal cell carcinoma: Current capabilities of drug treatment. Practical Oncology, 15(3), 185–195.

Pal, S., Sadhu, A. S., Patra, S., & Mukherjea, K. (2008). Histological vis-a-vis biochemical assessment on the toxic level and antineoplastic efficacy of a synthetic drug Pt-ATP on experimental animal models. Journal of Experimental and Clinical Cancer Research, 68, 98–112. >> doi.org/10.1186/1756-9966-27-68